Bryan Bottarelli, Head Trade Tactician, Monument Traders Alliance Publisher's Note: Jon Najarian sold his first trading system for over a billion dollars. Now he's built something that could be even bigger. On February 4 at 2 p.m. ET, Jon's joining Bryan live to demonstrate his new AI Trade Monster - a patent-pending system designed to detect entries and exits before massive stock moves. This isn't theory. Jon's early access group already hit six 100% winners in the first month using this tool. During the summit, you'll see the AI in action, learn how it works, and get Jon's No. 1 trade recommendation completely free. Reserve your spot now. This advantage won't stay hidden for long. Reserve Your FREE Spot Here - Stephen Prior, Publisher
Dear Reader, I have to admit something... When Corcept Therapeutics (CORT) hit our Gift Gap scanner on January 22, I had absolutely no clue what this company did. Never traded it. Never researched it. Complete blank. But here's the thing about Gift Gap trades... that doesn't matter. When you see a perfect setup, you see it. And this was one of the cleanest I've spotted all year. This Gift Gap scanner alert that we emailed out looked exactly like this… That gap showed up after the FDA declined to approve Corcept's drug for rare hormonal disorder. While investors panic-sold... I saw something different: a fundamentally strong company getting hammered by an overreaction. Here's what the crowd missed while they were selling... Corcept's Q3 revenues jumped to $207.6 million from $182.5 million year over year. Management reaffirmed their $800 million to $850 million full-year guidance. They're sitting on $524 million cash - enough runway to weather any clinical setbacks. The FDA said "not yet" to one drug. The market acted like they said "never" to the entire company. That gap from $70 down to $35? Pure emotional selling creating our gift opportunity. | 
0 Response to "♟ How to Turn an FDA Panic-Sell Into 25% Profits in 5 Days"
Post a Comment